Peptide Inhibitors
Peptide Inhibitors - Related Videos
06:06
Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
0 Views •
Cited by 5 •
2019
We have previously used a gold nanoparticle peptide hybrid to intravenously deliver a synthetic peptide, protein kinase C-delta inhibitor, which reduced ischemia-reperfusion-induced acute lung injury. Here we show the detailed protocol of the drug formulation. Other intracellular peptides can be formulated similarly.
12:27
Measuring Peptide Translocation into Large Unilamellar Vesicles
0 Views •
Cited by 9 •
2012
This protocol details a method for the quantitative measure of peptide translocation into large unilamellar lipid vesicles. This method also provides information about the rate of membrane translocation and can be used to identify peptides that efficiently and spontaneously cross lipid bilayers.
10:33
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
0 Views •
Cited by 4 •
2015
We describe implementation of the REPLACE strategy for targeting protein-protein interactions. REPLACE is an iterative strategy involving synthetic and computational approaches for the conversion of optimized peptidic inhibitors into drug like molecules.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
04:00
Immunoaffinity Based Extraction of Ubiquitinylated Peptides: A Technique to Selectively Extract Ubiquitin Tagged Peptides from Purified Peptide Fractions
0 Views •
2023
This video describes a method to extract and purify ubiquitinylated peptides containing remnant di-glycine peptides from a complex peptide mixture. The presented method may help in identifying original ubiquitination sites in the protein.
FAQs
Sequence and three-dimensional structure determine whether a peptide inhibitor fits its protein target and maintains the contacts needed for binding. Concentration affects how much target protein is occupied, while binding affinity describes the strength of that interaction. Together, these variables help explain why two peptide inhibitors can produce different levels of inhibition against the same protein.
Blocking an active site prevents substrate recognition or the catalytic reaction itself. Binding elsewhere can disrupt a protein-protein interaction or restrict a conformational change, meaning the protein can be inhibited without directly occupying its catalytic center. This distinction helps biologists connect a peptide’s binding location with the particular molecular step that has been interrupted.
An inhibitory effect can be interpreted at several biological levels. At the protein level, activity falls; at the pathway level, downstream signaling or enzyme-dependent events may change. By linking a selected protein to these effects, investigators can use peptide inhibitors as probes to test enzyme function, examine signaling control, and clarify how a pathway operates.
To use one in pathway research, investigators select a peptide directed at a protein of interest, expose the biological system to an appropriate concentration, and examine the resulting change in protein activity or pathway behavior. Comparing inhibited and uninhibited conditions can help associate the target protein with enzyme function, signaling events, or disease-related mechanisms.
Peptide inhibitors can serve as starting points for targeted therapy because they act on specific proteins rather than broadly affecting unrelated processes. Their therapeutic promise depends not only on target binding but also on performance in living systems. Stability, cellular delivery, and resistance to enzymatic degradation may determine whether an inhibitor remains effective long enough to produce the intended biological effect.
Concentration and binding affinity are especially important when interpreting experimental results. A weakly binding peptide may show limited inhibition, whereas insufficient concentration may leave much of the target active. Observed pathway changes should also be related to the inhibitor’s intended protein and binding mode, because active-site blockade, interaction disruption, and conformational interference produce different mechanistic interpretations.
In disease-mechanism studies, a peptide inhibitor can help test whether a particular protein contributes to abnormal enzyme activity or signaling. If reducing that protein’s function changes the relevant biological response, the result supports a connection between the target and the mechanism under investigation. Such findings can guide further evaluation of the protein as a therapeutic target.